Multiply robust estimation of principal causal effects with noncompliance and survival outcomes

被引:2
作者
Cheng, Chao [1 ]
Guo, Yueqi [2 ]
Liu, Bo [2 ]
Wruck, Lisa [3 ,4 ]
Li, Fan [1 ,2 ]
Li, Fan [1 ,2 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, Suite 200,Room 229,135 Coll St, New Haven, CT 06510 USA
[2] Duke Univ, Dept Stat Sci, Durham, NC USA
[3] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA
[4] Duke Clin Res Inst, Durham, NC USA
基金
美国国家卫生研究院;
关键词
Causal inference; estimands; principal stratification; pragmatic clinical trials; sensitivity analysis; survival analysis; RANDOMIZED-TRIAL; MODELS;
D O I
10.1177/17407745241251773
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Treatment noncompliance and censoring are two common complications in clinical trials. Motivated by the ADAPTABLE pragmatic clinical trial, we develop methods for assessing treatment effects in the presence of treatment noncompliance with a right-censored survival outcome. We classify the participants into principal strata, defined by their joint potential compliance status under treatment and control. We propose a multiply robust estimator for the causal effects on the survival probability scale within each principal stratum. This estimator is consistent even if one, sometimes two, of the four working models-on the treatment assignment, the principal strata, censoring, and the outcome-is misspecified. A sensitivity analysis strategy is developed to address violations of key identification assumptions, the principal ignorability and monotonicity. We apply the proposed approach to the ADAPTABLE trial to study the causal effect of taking low- versus high-dosage aspirin on all-cause mortality and hospitalization from cardiovascular diseases.
引用
收藏
页码:553 / 561
页数:9
相关论文
共 23 条
[1]   Doubly-Robust Estimators of Treatment-Specific Survival Distributions in Observational Studies with Stratified Sampling [J].
Bai, Xiaofei ;
Tsiatis, Anastasios A. ;
O'Brien, Sean M. .
BIOMETRICS, 2013, 69 (04) :830-839
[2]   Analysis of survival data from a randomized trial with all-or-none compliance: Estimating the cost-effectiveness of a cancer screening program [J].
Baker, SG .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1998, 93 (443) :929-934
[3]  
Cheng C., 2023, ARXIV PREPRINT
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination [J].
Cuzick, Jack ;
Sasieni, Peter ;
Myles, Jonathan ;
Tyrer, Jonathan .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2007, 69 :565-588
[6]   Principal stratification analysis using principal scores [J].
Ding, Peng ;
Lu, Jiannan .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2017, 79 (03) :757-777
[7]   Biological, clinical, and ethical advances of placebo effects [J].
Finniss, Damien G. ;
Kaptchuk, Ted J. ;
Miller, Franklin ;
Benedetti, Fabrizio .
LANCET, 2010, 375 (9715) :686-695
[8]   Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes [J].
Frangakis, CE ;
Rubin, DB .
BIOMETRIKA, 1999, 86 (02) :365-379
[9]  
Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221
[10]  
Hirano K, 2000, Biostatistics, V1, P69, DOI 10.1093/biostatistics/1.1.69